loading-logo

Loading...

Description

Scroll To Explore

Description
Project Background
Existing Solutions and Challenges
Our Solution
Follow-up Optimization Tasks
Future Prospects
Reference 
1. Project Background

Microplastics refer to plastic particles with a diameter less than 5 mm. Based on their source, they can be classified as primary microplastics, such as abrasive particles in toothpaste and facial cleansers, and secondary microplastics formed from the environmental degradation and fragmentation of plastic products. In recent years, with the extensive use and improper disposal of plastic products, microplastics have become a global environmental pollution issue.

These ubiquitous microplastics can enter the human body through various pathways, including inhalation, diet, and daily use products. Studies indicate that an average of 325 microplastic particles can be detected per liter of bottled water, and urban residents may inhale approximately 32,000 microplastic particles annually through respiration[1]. These invading microplastics can further breach various biological barriers in the human body, widely existing in blood, brain, liver, kidneys, placenta, and other organs, where they can persistently accumulate[2].

Fig 1. The spread of microplastics.

Fig 1. The spread of microplastics

Simultaneously, microplastics can act as carriers, adsorbing toxic substances such as heavy metals and organic pollutants, forming composite pollutants that exacerbate their biological toxicity to humans[3]. Epidemiological data suggests that microplastic exposure is associated with various human health risks, including gastrointestinal inflammation, abnormal immune responses, and tumors[4]. Notably, microplastics can also affect sperm motility[5] and can be transferred to fetuses via the placenta, indicating their potential for transgenerational health effects[6].

Since the environmental pollution problem of microplastics cannot be completely resolved, we are focusing on the human gut. We aim to employ synthetic biology strategies to design and develop an engineered yeast-based microplastic degradation system. This system is intended to specifically recognize, adsorb, and degrade microplastics within the human intestinal tract, while also repairing intestinal mucosal damage caused by microplastics. The goal is to minimize the accumulation of microplastics in the human body and their potential health risks, offering a novel biological remediation strategy to address the global health challenges posed by microplastic pollution[7].

2. Existing Solutions and Challenges

Microplastics are widely distributed across various environmental media, including oceans, freshwater, soil, and the atmosphere. Humans inevitably and continuously ingest microplastics through multiple routes such as diet and respiration[3]. These microplastics entering the body can migrate via blood circulation to multiple organs throughout the body, posing serious health threats. Unfortunately, no clinical drugs currently exist that can specifically recognize, capture, or degrade microplastics within the body[8].Furthermore, the human immune system struggles to effectively clear these exogenous particles, leading to the continuous accumulation of microplastics in organisms and creating potential health risks. Facing this increasingly severe global health challenge, developing strategies for the removal of microplastics is particularly urgent.

Fig 2. The challenges and our conceptions.

Fig 2. The challenges and our conceptions

3. Our Solution

The engineered yeast we have designed features an efficient "Microplastic Clearance System," capable of precisely executing multiple tasks within the human intestinal tract. Tailored to the characteristics of the intestinal environment, each engineered yeast cell integrates three core functional modules. Upon ingestion of products containing these engineered yeasts, the clearance units initiate a scouting mechanism, rapidly adapting to the low-oxygen, weakly alkaline microenvironment of the gut. Through intercellular signaling, they aggregate and preliminarily establish an intestinal barrier.

As feeding activities occur, glucose produced from food breakdown in the intestine activates the clearance units, triggering their signal recruitment and coordinated response mechanisms, while simultaneously initiating the degradation module. Leveraging specific adhesive proteins, the clearance units efficiently bind to microplastics and secrete degrading enzymes that break down the captured microplastics into harmless small molecules, achieving complete clearance. Furthermore, the system enhances the intestinal barrier and provides therapeutic benefits by alleviating mucosal oxidative damage and promoting tissue regeneration through its repair module, thereby treating intestinal inflammatory responses and preventing further harm from microplastics.

After completing their tasks, excess or impaired clearance units are excreted via feces and undergo self-digestion, ensuring no residual presence in the intestine or natural environment. This design guarantees both effective functionality within the body and eliminates potential ecological risks.

3.1 Enzymatic Degradation Module

(1) BAR1 Gene and Effector Protein Expression: 

In this study, we employed CRISPR/dCas technology to construct a logic genetic switch. This device features a stringent conditional triggering mechanism: downstream target gene expression is activated only when three necessary conditions are simultaneously met (detection of high postprandial intestinal glucose concentration + the presence of copper ions in the human gut + the specific hypoxic environment of the intestines). Downstream of these three condition-specific promoters are linked the three essential components required for the CRISPR/dCas9 system: the dCas binding protein,the guide RNA,and the repressor domain MXI.

We plan to design a corresponding scRNA targeting the upstream region of BAR1.Only when all three components are co-expressed will they assemble and bind to the constitutive promoter PBAR1, thereby inhibiting the expression of the BAR1 gene.As a result, α-factor is not degraded (α-factor is a crucial component of the quorum sensing system), allowing the quorum sensing system to proceed normally.

Fig 3. Expression of the BAR1 gene & effector proteins.

Fig 3. Expression of the BAR1 gene & effector proteins

(2) Quorum Sensing-Controlled Degradation Enzyme Expression: 

To prevent premature enzyme expression from affecting bacterial growth and reducing efficiency, we incorporated a quorum sensing system to monitor its growth status. Only when the engineered bacteria reach a certain density within the intestine and the upstream conditions are met (presence of α-factor), the FUS1 promoter controlling enzyme expression is activated. Subsequently,the downstream PET-degrading enzyme and MHET-degrading enzyme are expressed and,guided by the α-factor signal peptide, secreted outside the engineered bacteria.This leads to further amplification of expression,enabling efficient degradation of microplastics.

Fig 4. Degradation enzyme expression controlled by group sensing.

Fig 4. Degradation enzyme expression controlled by group sensing

3.2 Adsorption Module

Based on literature, we learned that the adsorption of microplastics can enhance the efficacy of enzymatic degradation[9][10]. Since hydrophobin HFBI demonstrates high adsorption affinity for PET microplastics[11], we utilized the α-agglutinin system of Saccharomyces cerevisiae to construct a surface display system for the constitutive expression of HFBI. AGA1 and AGA2 form a complex linked by a disulfide bond intracellularly, and are subsequently displayed on the cell surface via the Aga2sp signal peptide. The V5 epitope tag was incorporated to enable validation of expression without interfering with HFBI's function. Consequently, the engineered Saccharomyces cerevisiae gains the capability to adhere to the surface of PET materials.

Fig 5. The absorption mechanism of the yeast.

Fig 5. The absorption mechanism of the yeast

Furthermore, we noted that in Saccharomyces cerevisiae with gal80 knockout, the use of the gal1,10 promoter enables dynamic regulation of gene expression. This system allows for inducible expression under low glucose conditions—such as during non-feeding periods—which operates orthogonally to the degradation module. The degradation module is activated during feeding, i.e., under high glucose conditions. This temporal separation in the expression of the two modules helps reduce the metabolic burden on the yeast cells, thereby minimizing potential cytotoxicity.

Fig 6. Dynamic regulation mechanism of yeast.

Fig 6. Dynamic regulation mechanism of yeast

3.3 Therapeutic Module

We designed a multigene co-expression cassette driven by the GPX2 promoter, constructing an integrated functional module for "antioxidation–mucosal repair–oxidative clearance". The cassette structure is GPX2→NCW2-SOD1→P2A→NCW2-TFF3→T2A→NCW2-CTT1. This design utilizes 2A peptides to enable the continuous expression and self-cleavage of the three functional proteins. An NCW2 signal peptide is introduced before each protein to direct their extracellular secretion, ensuring efficient release and function of the proteins in the intestinal environment. Within this system, SOD1 serves as the first line of defense by scavenging superoxide anions, TFF3 promotes intestinal mucosal repair, and CTT1 decomposes hydrogen peroxide. Together with SOD1, they form a cascade reaction that synergistically clears oxidative stress products, thereby achieving an integrated protective effect of response, repair, and clearance in the gut.

Fig.14.Lactic acid bacteria co-aggregate with S.cerevisiae through Msa protein.

Fig 7. Multi-gene co-expression circuit

3.4 Symbiosis Module
Fig.14.Lactic acid bacteria co-aggregate with S.cerevisiae through Msa protein.

Fig 8. The symbiotic system of Saccharomyces cerevisiae and Lactobacillus plantarum

Fig.9.Lactic acid bacteria co-aggregate with S.cerevisiae through Msa protein.

Fig 9. Lactobacillus plantarum co-aggregate with S.cerevisiae through Msa protein

Building upon the adsorption module, the engineered yeast surface-displays hydrophobin HFBI, enabling active adsorption of microplastics. Simultaneously, Lactiplantibacillus strains also adsorb microplastics and, through the mediation of the Msa protein, co-aggregate with the yeast to form a biofilm. This structure facilitates the establishment and maintenance of a stable symbiotic system.

Fig10.Metabolic complementary symbiotic mechanisms between S.cerevisiae and LAB.

Fig 10. Metabolic complementary symbiotic mechanisms between S.cerevisiae and LAB

This figure illustrates the mechanism of metabolic cross-feeding and symbiosis between Saccharomyces cerevisiae and Lactiplantibacillus. In this system, Lactiplantibacillus breaks down exogenous lactose, releasing galactose as a carbon source for the yeast. Concurrently, metabolic byproducts such as lactic acid or acetic acid can induce the yeast to reduce ethanol production, thereby creating a more favorable environment for Lactiplantibacillus. In return, the yeast secretes growth factors—including amino acids, riboflavin, and CO₂—via nitrogen overflow, which support the growth of Lactiplantibacillus. Additionally, under bile salt-induced stress, the yeast produces a reactivation factor that exhibits protective effects on Lactiplantibacillus.Collectively, this symbiotic system demonstrates immunomodulatory capabilities characterized by both pro- and anti-inflammatory effects, contributing to the alleviation of microplastic-induced intestinal inflammation.

Lactobacillus can bind to adhesion sites on the human intestinal epithelium, mediating colonization.

We discovered a strain called Lactobacillus plantarum DT88, which not only has the potential to co-aggregate with yeast but also exhibits a strong ability to adsorb microplastics on its own.

3.5 Safety module

(1) In Vivo Biosafety — L-Arabinose

Toxin/Antitoxin System:The Endogenous K1 Killer Toxin System in Saccharomyces cerevisiae.This system is naturally present in certain yeast strains and is encoded by viral dsRNA. The K1 killer precursor protein functions as an antitoxin, counteracting the toxicity of the mature K1 killer toxin. We utilized a common food additive—arabinose—to achieve in vivo safety control. In the absence of arabinose in the gut, the K1 killer precursor protein is induced and expressed, providing antitoxin activity. Conversely, upon arabinose intake, the mature K1 killer toxin accumulates, depletes the antitoxin, and ultimately induces cell death.

Fig.12.The suicide mechanism of the yeast.

Fig 11. The suicide mechanism of the yeast

(2) Ex Vivo Biosafety

Due to the temperature difference between the internal and external environments, we employed a temperature-sensitive promoter to regulate an external safety circuit. The HSP26 promoter is induced at temperatures above 37°C, leading to the expression of tetR, which represses the Ptet promoter and prevents the activation of the downstream killer module. Once the engineered yeast is excreted into the external environment where the temperature is insufficient for induction, the killer module is expressed.

For the killer module, we targeted nucleic acid metabolism. First, we identified a core gene in yeast nucleic acid metabolism that encodes phosphoribosylaminoimidazole carboxylase, a key enzyme in the de novo purine biosynthesis pathway. Knocking out ADE2 results in an adenine auxotrophic yeast strain that cannot survive in adenine-deficient environments[12].

Fig.13.ADE2-regulated suicide mechanism.

Fig 12. ADE2-regulated suicide mechanism

Second, we introduced a heterologous nuclease gene, nucA, which has been previously demonstrated to function in Saccharomyces cerevisiae[13]. We placed the nucA gene from Serratia marcescens under the control of the glucose-repressible ADH2 promoter. In the glucose-rich intestinal environment, the ADH2 promoter remains repressed, and nucA is not expressed, allowing the yeast to survive normally. However, if the engineered bacteria escape into external environments with scarce glucose, such as soil or water, the ADH2 promoter becomes activated. This leads to the production of nuclease, which degrades the host cell's genetic material and causes cell death.

Fig.14.NucA-regulated suicide mechanism.

Fig 13. NucA-regulated suicide mechanism

4. Follow-up Optimization Tasks

The next phase of our project will focus on two core pathways: First, we will comprehensively translate current computer designs into reliable functions validated through wet-lab experiments. This includes: testing the degradation function of the “three-input AND gate” intelligent control system; verifying the actual efficacy of the anti-inflammatory and antioxidant modules at the cellular level; obtaining Lactobacillus plantarum for symbiotic system construction; and establishing a multi-layered safety architecture for the genetic circuit and “spore-free” chassis.

Building upon this foundation, we will integrate more forward-looking engineering enhancements designed to elevate project performance and safety to unprecedented levels:

(1) Degradation Module: The core modification involves constructing a PETase-MHETase fusion protein to enhance catalytic efficiency. By optimizing metabolic flux and alleviating endoplasmic reticulum stress, this approach clears obstacles for efficient protein secretion, achieving a leap from “smart expression” to “high yield.”

(2) Adsorption Module: Optimization focuses on enhancing surface display efficiency. This involves co-expressing the Aga1 gene to increase display “anchor points” and exploring more efficient signal peptides and GPI anchoring systems as alternative solutions.

(3) Anti-inflammatory and Antioxidant Module: The design philosophy evolves from a “fixed formula” to an “intelligent cocktail therapy.” By introducing IRES elements of varying strengths, it enables precise non-equimolar regulation of multiple therapeutic proteins to adapt to different stages of inflammation.

(4) Safety Module: Building upon validated in vivo/in vitro suicide switches, a “dual-insurance” design is implemented. Under the same induction signal, two distinct killing systems (e.g., K1 toxin and dCas9-KRAB) with fundamentally different mechanisms activate in parallel. This prevents failure due to single-point mutations, significantly enhancing system robustness.

5. Future Prospects

We are confident about the future. Our project remains closely connected to the forefront of synthetic biology exploration and global sustainable development goals. We hope our designed engineered yeast can play an important role in solving problems for all humanity. We plan to further optimize the system performance of the engineered yeast, advance its safety and efficacy validation in real human environments, and actively explore its application potential in various fields such as environmental remediation and health intervention. We anticipate that this synthetic biology-based microplastic removal technology could not only develop into a novel tool for personal health management but also become a green, safe, and scalable biological solution to address global microplastic pollution. We are hopeful for the future and will continue to advance the project, striving to translate laboratory achievements into public goods with global significance, providing technological support for building a cleaner and healthier future, and creating a better tomorrow for humanity.

Reference

1. Jenner LC, Rotchell JM, Bennett RT, Cowen M, Tentzeris V, Sadofsky LR. Detection of microplastics in human lung tissue using μFTIR spectroscopy. Sci Total Environ. 2022 Jul 20;831:154907. doi: 10.1016/j.scitotenv.2022.154907. Epub 2022 Mar 29. PMID: 35364151.

2. Roslan NS, Lee YY, Ibrahim YS, Tuan Anuar S, Yusof KMKK, Lai LA, Brentnall T. Detection of microplastics in human tissues and organs: A scoping review. J Glob Health. 2024 Aug 23;14:04179. doi: 10.7189/jogh.14.04179. PMID: 39175335; PMCID: PMC11342020.

3. Cózar A, Echevarría F, González-Gordillo JI, Irigoien X, Ubeda B, Hernández-León S, Palma AT, Navarro S, García-de-Lomas J, Ruiz A, Fernández-de-Puelles ML, Duarte CM. Plastic debris in the open ocean. Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10239-44. doi: 10.1073/pnas.1314705111. Epub 2014 Jun 30. PMID: 24982135; PMCID: PMC4104848.

4. Schwabl P, Köppel S, Königshofer P, Bucsics T, Trauner M, Reiberger T, Liebmann B. Detection of Various Microplastics in Human Stool: A Prospective Case Series. Ann Intern Med. 2019 Oct 1;171(7):453-457. doi: 10.7326/M19-0618. Epub 2019 Sep 3. PMID: 31476765.

5. Filomena Mottola, Maria Carannante, Angela Barretta, Ilaria Palmieri, Lucia Rocco,Reproductive cytotoxic and genotoxic impact of polystyrene microplastic on Paracentrotus lividus spermatozoa,Current Research in Toxicology,Volume 6,2024,100173,ISSN 2666-027X,https://doi.org/10.1016/j.crtox.2024.100173.

6. Zhang GS, Liu YF. The distribution of microplastics in soil aggregate fractions in southwestern China. Sci Total Environ. 2018 Nov 15;642:12-20. doi: 10.1016/j.scitotenv.2018.06.004. Epub 2018 Jun 9. PMID: 29894871.

7. Yang Y, Liu W, Zhang Z, Grossart HP, Gadd GM. Microplastics provide new microbial niches in aquatic environments. Appl Microbiol Biotechnol. 2020 Aug;104(15):6501-6511. doi: 10.1007/s00253-020-10704-x. Epub 2020 Jun 4. PMID: 32500269; PMCID: PMC7347703.

8. Smith M, Love DC, Rochman CM, Neff RA. Microplastics in Seafood and the Implications for Human Health. Curr Environ Health Rep. 2018 Sep;5(3):375-386. doi: 10.1007/s40572-018-0206-z. PMID: 30116998; PMCID: PMC6132564.

9. Zhang W, Han Y, Yang F, Guan L, Lu F, Mao S, Tian K, Yao M, Qin HM. A customized self-assembled synergistic biocatalyst for plastic depolymerization. J Hazard Mater. 2024 Sep 15;477:135380. doi: 10.1016/j.jhazmat.2024.135380. Epub 2024 Jul 30. PMID: 39088944.

10. Chen Z, Duan R, Xiao Y, Wei Y, Zhang H, Sun X, Wang S, Cheng Y, Wang X, Tong S, Yao Y, Zhu C, Yang H, Wang Y, Wang Z. Biodegradation of highly crystallized poly(ethylene terephthalate) through cell surface codisplay of bacterial PETase and hydrophobin. Nat Commun. 2022 Nov 21;13(1):7138. doi: 10.1038/s41467-022-34908-z. PMID: 36414665; PMCID: PMC9681837.

11. Andreu C, Gómez-Peinado J, Winandy L, Fischer R, Del Olmo ML. Surface display of HFBI and DewA hydrophobins on Saccharomyces cerevisiae modifies tolerance to several adverse conditions and biocatalytic performance. Appl Microbiol Biotechnol. 2021 Feb;105(4):1505-1518. doi: 10.1007/s00253-021-11090-8. Epub 2021 Jan 23. PMID: 33484321.

12. Kokina A, Kibilds J, Liepins J. Adenine auxotrophy--be aware: some effects of adenine auxotrophy in Saccharomyces cerevisiae strain W303-1A. FEMS Yeast Res. 2014 Aug;14(5):697-707. doi: 10.1111/1567-1364.12154. Epub 2014 Apr 11. PMID: 24661329.

13. Balan A, Schenberg AC. A conditional suicide system for Saccharomyces cerevisiae relying on the intracellular production of the Serratia marcescens nuclease. Yeast. 2005 Feb;22(3):203-12. doi: 10.1002/yea.1203. PMID: 15704225.

icon
您的浏览器不支持canvas